Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations
Eiji Iwama(Kyushu University), Isamu Okamoto(Kyushu University Hospital), Kazuto Nishio(Kindai University Sakai Hospital), Gen Kida(Saitama Cancer Center), Kazuko Sakai(Kindai University Sakai Hospital), Yasuhiko Nishioka(Tokushima University), Toshihide Yokoyama(Kurashiki Central Hospital), Nobuyuki Yamamoto(Wakayama Medical University), Hirokazu Taniguchi(Memorial Sloan Kettering Cancer Center), Hiroshi Yokouchi(National Hospital Organization Hokkaido Medical Center), Yoshitaka Zenke(National Cancer Center Hospital East), K. Koyama(Aichi Medical University), Shunichi Sugawara(Sendai Kousei Hospital), Masayuki Hirose(Kyushu University Hospital), Yuichiro Ohe(National Cancer Center), Taishi Harada(Fukuyama City Hospital), Ryo Toyozawa(National Hospital Organization Kyushu Cancer Center), Kaoru Tanaka(Kindai University), Shintaro Kanda(Shinshu University Hospital)
Cited by 3
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k